National trends in antidepressant medication treatment among publicly insured pregnant women

General Hospital Psychiatry

Volumn 35, Issue 3, 2013, Pages 265-271

  Huybrechts, Krista F ^a   Palmsten, Kristin ^b   Mogun, Helen ^a   Kowal, Mary ^a   Avorn, Jerry ^a   Setoguchi Iwata, Soko ^c   Hernández Díaz, Sonia ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Medicaid; National cohort; Patterns of medication use; Pregnancy

Indexed keywords

ANTIDEPRESSANT AGENT; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONCEPTION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; PREGNANT WOMAN; PUBLIC HEALTH INSURANCE; PUERPERAL DEPRESSION; PULMONARY HYPERTENSION; SUICIDE; TIME SERIES ANALYSIS;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; CHILD; COHORT STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; MEDICAID; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; UNITED STATES; YOUNG ADULT;

EID: 84876960656     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.12.010     Document Type: Article

References (41)

1. Blazer D.G., Kessler R.C., McGonagle K.A., Swartz M.S. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994, 151(7):979-986.
2. Evans J., Heron J., Francomb H., Oke S., Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001, 323(7307):257-260.
3. Cohen L.S., Altshuler L.L., Harlow B.L., Nonacs R., Newport D.J., Viguera A.C., et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006, 295(5):499-507.
4. Dietz P., Williams S., Callaghan W., Bachman D., Whitlock E., Hornbrook M. Clinically identified maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry 2007, 164:1515-1520.
5. Holzman C., Eyster J., Tiedje L., Roman L., Seagull E., Rahbar M. A life course perspective on depressive symptoms in mid-pregnancy. Matern Child Health J 2006, 10(2):127-138.
6. Cooper W.O., Willy M.E., Pont S.J., Ray W.A. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007, 196(6):544e541-544e545.
7. Andrade S.E., Raebel M.A., Brown J., Lane K., Livingston J., Boudreau D., et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008, 198(2):194e191-194e195.
8. Kaufman D.W., Kelly J.P., Rosenberg L., Anderson T.E., Mitchell A.A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002, 287(3):337-344.
9. Mitchell A., Gilboa S., Werler M., Kelley K., Louik C., Hernandez-Diaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011, 205(1):51.e51-51.e58.
10. Bonari L., Pinto N., Ahn E., Einarson A., Steiner M., Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004, 49(11):726-735.
11. Hirschfeld R.M., Keller M.B., Panico S., Arons B.S., Barlow D., Davidoff F., et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997, 277(4):333-340.
12. Yonkers K., Wisner K., Stewart D., Oberlander T., Dell D., Stotland N., et al. The management of depression: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009, 31:403-413.
13. Davis E., Glynn L., Schetter C., Hobel C., Chics-Demet A., Sandman C. Prenatal exposure to maternal depression and cortisol influences infant temperament. J Am Acad Child Adolesc Psychiatry 2007, 46:737-746.
14. Leech S., Larkby C., Day R., Day N. Predictors and correlates of high levels of depression and anxiety symptoms among children at age 10. J Am Acad Child Adolesc Psychiatry 2006, 45:223-230.
15. Field T., Diego M., Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 2006, 29:445-455.
16. Yonkers K.A., Wisner K.L., Stewart D.E., Oberlander T.F., Dell D.L., Stotland N., et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009, 31(5):403-413.
17. Stewart D. Depression during pregnancy. N Engl J Med 2011, 365:1605-1611.
18. Louik C., Lin A.E., Werler M.M., Hernandez-Diaz S., Mitchell A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007, 356(26):2675-2683.
19. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S., Friedman J.M. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007, 356(26):2684-2692.
20. Berard A., Ramos E., Rey E., Blais L., St-Andre M., Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007, 80(1):18-27.
21. Cole J.A., Ephross S.A., Cosmatos I.S., Walker A.M. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16(10):1075-1085.
22. Wogelius P., Norgaard M., Gislum M., Pedersen L., Munk E., Mortensen P.B., et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006, 17(6):701-704.
23. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354(6):579-587.
24. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335(14):1010-1015.
25. Davis R.L., Rubanowice D., McPhillips H., Raebel M.A., Andrade S.E., Smith D., et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007, 16(10):1086-1094.
26. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004, 158(4):312-316.
27. Wen S.W., Yang Q., Garner P., Fraser W., Olatunbosun O., Nimrod C., et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006, 194(4):961-966.
28. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006, 63(8):898-906.
29. Costei A.M., Kozer E., Ho T., Ito S., Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002, 156(11):1129-1132.
30. Garcia G. Maternal and Child Health (MCH) update: states increase eligibility for children's health in 2007 Electronic citation. Available at:, Accessed March 5, 2012. http://www.nga.org/files/live/sites/NGA/files/pdf/0811MCHUPDATE.PDF;jsessionid=7B47A647247DD4E5CB9B709C8F9797AE.
31. Palmsten K., Huybrechts K., Mogun H., Setoguchi S., Hernandez-Diaz S. Medicaid Analytic eXtract for studies of drug safety during pregnancy. Pharmacoepidemiol Drug Saf 2011, 20(Suppl. 1):S266.
32. Margulis V., Setoguchi S., Hernandez-Diaz S. A claims-based algorithm to estimate the date of the last menstrual period. Pharmacoepidemiol Drug Saf 2010, 19(Suppl. 1):s300.
33. Wagner A., Soumerai S., Zhang F., Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002, 27:299-309.
34. Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., Coyle M.G., Arria A.M., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010, 363(24):2320-2331.
35. Sclar D., Robison L., Schmidt J., Bowen K., Castillo L., Oganov A. Diagnosis of depression and use of antidepressant pharmacotherapy among adults in the United States: does a disparity persist by ethnicity/race?. Clin Drug Investig 2012, 32(2):139-144.
36. West S., Savitz D., Koch G., Strom B., Guess H., Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995, 142(10):1103-1112.
37. West S., Strom B., Freundlich B., Normand E., Koch G., Savitz D. Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol 1994, 47(2):165-167.
38. Levy A.R., O'Brien B.J., Sellors C., Grootendorst P., Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003, 10(2):67-71.
39. McKenzie D.A., Semradek J., McFarland B.H., Mullooly J.P., McCamant L.E. The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 2000, 53(12):1248-1257.
40. Toh S., Mitchell A., Werler M., Hernandez-Diaz S. Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. Am J Epidemiol 2008, 167(6):633-640.
41. Noyes K., Liu H., Lyness J., Friedman B. Medicare beneficiaries with depression: comparing diagnoses in claims data with the results of screening. Psychiatr Serv 2011, 62(10):1159-1166.